Skip to content
Sintilimab
Sintilimab is an antibody pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
282 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatocellular carcinomaD006528C22.01511311
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD0022898277——41
Liver neoplasmsD008113EFO_1001513C22.07194—531
Stomach neoplasmsD013274EFO_0003897C164192——20
Colorectal neoplasmsD0151791142—218
Esophageal squamous cell carcinomaD000077277184—114
Lung neoplasmsD008175C34.90361—111
ImmunotherapyD007167—81——9
Nasopharyngeal neoplasmsD009303—51—17
Renal cell carcinomaD002292—61——6
AdenocarcinomaD000230—31——4
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801412———23
Small cell lung carcinomaD055752—5———5
Uterine cervical neoplasmsD00258315———5
CholangiocarcinomaD018281C22.1—5———5
Healthy volunteers/patients—23———4
Squamous cell carcinoma of head and neckD000077195—4———4
Pancreatic neoplasmsD010190EFO_0003860C25—4———4
Large b-cell lymphoma diffuseD016403C83.3—3———3
Brain neoplasmsD001932EFO_0003833C71—2———2
Triple negative breast neoplasmsD064726—2———2
Show 30 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeuroblastomaD009447EFO_00006211————1
OsteosarcomaD0125161————1
Adenocarcinoma of lungD0000771921————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver diseasesD008107EFO_0001421K70-K77————11
ThrombosisD013927————11
MeningiomaD008579EFO_0003098D32.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSINTILIMAB
INNsintilimab
Description
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease, and has been approved in China.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID2072873-06-2
RxCUI—
ChEMBL IDCHEMBL4297829
ChEBI ID—
PubChem CID—
DrugBankDB15765
UNII ID8FU7FQ8UPK (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,219 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
26 adverse events reported
View more details